Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 38, Issue 6, 1998, Pages 492-495

  Gharaibeh, Munir N ^a   Gillen, Lisa P ^b   Osborne, Barbara ^b   Schwartz, Jules I ^c   Waldman, Scott A ^b,d  

^a UNIVERSITY OF JORDAN   (Jordan)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CYTOCHROME P450; ERYTHROMYCIN; RIFAMPICIN;

ADULT; ARTICLE; BREATH ANALYSIS; DRUG DETOXIFICATION; DRUG METABOLISM; DRUG SCREENING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RELIABILITY; REPRODUCIBILITY;

EID: 0031749374     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb05785.x     Document Type: Article

References (25)

1. Guengerich FP: Cytochrome P450 enzymes. Am Scientist 1993; 81:440-447.
2. Cholerton S, Daly AK, Idle JR: The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992;13:434-439.
3. Gonzalez FJ: Human cytochrome P450: problems and prospects. Trends Pharmacol Sci 1992;13:346-352.
4. Watkins PB: Breath tests as noninvasive assays of P450s. Methods Enzymol 1991;206:517-522.
5. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184.
6. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P450: studies in rats and patients. J Clin Invest 1989;83:688-697.
7. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kollars JC, Voorhees JJ: The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-129.
8. Turgeon DK, Normolle AB, Leichtman AB, Annesley TM, Smith DE, Watkins PB: Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-478.
9. Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, et al: Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 1997;61:531-543.
10. Tateishi T, Graham SG, Krivoruk Y, Wood AJ: Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test. Br J Clin Pharmacol 1995;40:411-412.
11. Krivoruk Y, Kinirons MT, Wood AJ, Wood M: Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994;56:608-614.
12. Hunt CM, Westerkam WR, Stave GM, Wilson JA: Hepatic cytochrome P-450A (CYP3A) activity in the elderly. Mech Ageing Dev 1992;64:189-199.
13. Metropolitan Life Insurance Company: 1983 Metropolitan height and weight tables. Statistical Bulletin: Metropolitan Life Foundation. 1983;64:3-9.
14. Austin KL, Mather LE, Philpot CR, McDonald PJ: Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273-279.
15. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB: The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
16. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJ: Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis. Clin Pharmacol Ther 1996;59:47-51.
17. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Waltington CO, et al: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992;51: 18-23.
18. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-955.
19. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, et al: The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P-450IIIA induction. Br J Clin Pharmacol 1989;28:373-387.
20. Bolt HM, Kappus H, Bolt M: Effect of rifampicin treatment on the metabolism of oestradiol and 17 alpha-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol 1975;8:301-307.
21. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878.
22. Ohnhaus EE, Breckenridge AM, Park BK: Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989;36:39-46.
23. Park BK, Breckenridge, AM: Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 1981;6:1-24.
24. Venkatesan K: Pharmacokinetic drug interactions with rifampin. Clin Pharmacokinet 1992;22:47-65.
25. Acocella G, Pagani V, Marchetti M, Baroni GC, Nicolis FB: Kinetic studies on rifampin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 1971;16:356-370.